John Rigg
Showing 1–2 of 2 transcripts.
- Milken Institute59 min
Reducing the Cost of Antimicrobial Resistance
Allan Coukell, Ella Balasa, Nick Crabb, Mark Feinberg, Jeremy Knox, Jenelle Krishnamoorthy, Alan Kockel, John Rigg, Robert Horn
This event convened global health experts to address the critical economic barriers and market failures preventing the development of new antimicrobials amidst rising resistance. Panelists highlighted the urgent need for innovative pull incentives, such as the UK's subscription model, to replace volume-based revenue while emphasizing that stewardship and rapid diagnostics are essential to preserve drug efficacy. The consensus called for immediate policy action to align public, private, and philanthropic resources across G20 nations to sustain the antibiotic innovation ecosystem before the window of opportunity closes.
- Milken Institute58 min
Redefining Philanthropic Drug Discovery
Emma Court, Bob Crutchfield, Kathy Giusti, John Rigg, Todd Sherer
Representative non-profits including the Multiple Myeloma Research Foundation, American Cancer Society, and Michael J. Fox Foundation are deploying specialized venture funds and pre-competitive consortia to accelerate drug development through strategic data ownership and direct investment. These entities face significant structural challenges regarding talent acquisition, donor reluctance to forgo financial returns, and the lack of viable reimbursement models for critical areas like antimicrobial stewardship. Panelists recommend that organizations conduct rigorous landscape assessments and adopt neutral, execution-focused investment strategies to bridge the gap between philanthropy and commercial innovation without crowding out private sector growth.